Crinetics Pharmaceuticals (CRNX) has had the highest return this quarter by a mid-cap US stock, returning 126.4%.
| ASSET | QUARTER | % RETURN |
|---|---|---|
Crinetics Pharmaceuticals (CRNX) | Q3 2026 | 126.35% |
Amylyx Pharmaceuticals (AMLX) | Q3 2026 | 109.98% |
NIQ Global Intelligence (NIQ) | Q3 2026 | 102.95% |
Iovance Biotherapeutics (IOVA) | Q3 2026 | 102.88% |
Wix (WIX) | Q3 2026 | 87.08% |
Xencor (XNCR) | Q3 2026 | 83.93% |
ManpowerGroup (MAN) | Q3 2026 | 81.71% |
Utz Brands (UTZ) | Q3 2026 | 81.53% |
CareDx (CDNA) | Q3 2026 | 76.94% |
Pulse Biosciences (PLSE) | Q3 2026 | 76.45% |
Huron Consulting (HURN) | Q3 2026 | 72.39% |
AtriCure (ATRC) | Q3 2026 | 72.2% |
WPP PLC ADR (WPP) | Q3 2026 | 70.63% |
Heartflow, Inc Common Stock (HTFL) | Q3 2026 | 69.98% |
Zhong Yang Financial Group Limited Ordinary Shares (TOP) | Q3 2026 | 69.83% |
10X Genomics (TXG) | Q3 2026 | 67.93% |
CBIZ (CBZ) | Q3 2026 | 66.72% |
Appian (APPN) | Q3 2026 | 66.3% |
Accelerant (ARX) | Q3 2026 | 65.16% |
NovaGold Resources (NG) | Q3 2026 | 64.2% |
Ringcentral (RNG) | Q3 2026 | 63.83% |
Rumble (RUM) | Q3 2026 | 62.9% |
Abcellera Biologics (ABCL) | Q3 2026 | 62.55% |
Paymentus (PAY) | Q3 2026 | 59.08% |
Aveanna Healthcare (AVAH) | Q3 2026 | 58.58% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.